



## Prior Authorization Approval Criteria

### *Trilipix (fenofibric acid)*

<b>Generic name:</b>	fenofibric acid
<b>Brand name:</b>	Trilipix
<b>Medication class:</b>	antihyperlipidemic
<b>FDA-approved uses:</b>	indicated as an adjunct to diet to reduce triglycerides, LDL-C , Total-C, and Apo B and increase HDL-C
<b>Available dosage forms:</b>	45 mg and 135 mg capsules
<b>Usual dose:</b>	Mixed dyslipidemia: 135 mg once daily Hypertriglyceridemia: 45-135 mg once daily Renally impaired: 45 mg once daily
<b>Approximate monthly cost:</b> (based on AWP 2009)	45 mg capsules: \$41.33 135 mg capsules: \$123.99
<b>Duration of therapy:</b>	Indefinite

**Criteria for use** (*bullet points below are all inclusive unless otherwise noted*):

- Patient must have hyperlipidemia.
- Must have tried and failed generic fenofibrate.

**Contraindication:**

- Severe renal dysfunction, including patients receiving dialysis
- Active liver disease
- Gallbladder disease
- Nursing mothers
- Hypersensitivity to fenofibric acid, choline fenofibrate, or fenofibrate

**Not approved if:**

- Does not meet the above stated criteria
- Has any contraindications to the use of Trilipix

**Special considerations:**

- Although fenofibrate has not been approved by the FDA for use in combination with statins, there are several trials evaluating the safety and efficacy of fenofibrate in combination with a statin. Based on available data, there appears to be no significant difference in the safety and efficacy of combining either Trilipix (fenofibric acid) or fenofibrate with a statin. Both fenofibrate and fenofibric acid appear to be relatively safe when combined with statins.

FCHP Pharmacy and Therapeutics Committee approval: \_\_\_\_\_

Date: \_\_\_\_\_

Adopted: 09/09/09